Durvalumab

FDA label information for this drug is available at DailyMed.

Use in Cancer

Durvalumab is approved to treat:

• Non-small cell lung cancer (NSCLC). It is used in patients with stage III NSCLC that cannot be removed by surgery and did not get worse after platinum chemotherapy and radiation therapy.
• Urothelial carcinoma (a type of bladder cancer) that is locally advanced or has metastasized (spread to other parts of the body). It is used in patients whose disease got worse during or after treatment with platinum chemotherapy. This use is approved under FDA’s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that durvalumab provides a clinical benefit in these patients.

Durvalumab is also being studied in the treatment of other types of cancer.

More About Durvalumab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Durvalumab - A lay language summary of important information about this drug that may include the following:

• warnings about this drug,
• what this drug is used for and how it is used,
• what you should tell your doctor before using this drug,
• what you should know about this drug before using it,
• other drugs that may interact with this drug, and
• possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Trial Results Highlight Changing Lung Cancer Treatment Landscape

Targeted Cancer Therapies

FDA Approves Three Immunotherapy Drugs for Patients with Bladder Cancer

Clinical Trials Accepting Patients

Find Clinical Trials for Durvalumab - Check for trials from NCI's list of cancer clinical trials now accepting patients.